Chemical pathology laboratories: green light, subject to conditions, to the take-over of Dyomedea-Neolab by Biogroup


The transaction does not give rise to any competition concerns on the upstream supply markets with suppliers or on the chemical pathology markets in most of the local areas examined. The Autorité did, however, consider that there were serious risks of harm to competition on the routine chemical pathology testing market in the Rhône département.

In order to maintain competitive intensity in this département, the new entity has agreed to sell off seven chemical pathology laboratory sites.  Four of these sites are owned by Biogroup; the other three are currently owned by Dyomedea-Neolab.

Print the page